Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.79 |
| ▸ | RAB9A | P51151 | 3/20 | 0.79 |
| ▸ | MEN1 | O00255 | 7/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.63 |
| ▸ | CA12 | O43570 | 4/20 | 0.62 |
| ▸ | CA1 | P00915 | 4/20 | 0.62 |
| ▸ | CA2 | P00918 | 4/20 | 0.62 |
| ▸ | CA9 | Q16790 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8772924 | 0.89 | RAB9A (1.00) | MAPTRAB9AMEN1KMT2ACA12 | |
| SCHEMBL11048619 | 0.89 | MEN1 (0.76) | MAPTRAB9AMEN1KMT2ACA12 | |
| SCHEMBL4741253 | 0.89 | MEN1 (0.76) | MAPTRAB9AMEN1KMT2ACA12 | |
| SCHEMBL7643264 | 0.86 | MAPT (0.70) | MAPTRAB9AMEN1KMT2ACA12 | |
| SCHEMBL678618 | 0.82 | KMT2A (0.81) | MAPTRAB9AMEN1KMT2ACA12 | |
| SCHEMBL684089 | 0.82 | KMT2A (0.81) | MAPTRAB9AMEN1KMT2ACA12 | |
| SCHEMBL12973528 | 0.81 | EPHX1 (0.79) | MAPTRAB9AMEN1KMT2ACA12 | |
| SCHEMBL4105004 | 0.81 | CNR1 (0.74) | MAPTRAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL5650525 | 0.81 | MAOA (0.67) | MAPTRAB9AMEN1KMT2ACA12 | |
| SCHEMBL546369 | 0.81 | RAB9A (0.83) | MAPTRAB9AMEN1KMT2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390591-B2 | 2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof | ALUDA PHARMACEUTICALS, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3456712-B1 | NOVEL 2,4,6-TRISUBSTITUTED S-TRIAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | NANJING SHIQI PHARMACEUTICAL CO LTD (CN) | 2022-04-20 | — | — | EP | disclosed |
| CN-109311825-B | 2,4, 6-trisubstituted s-triazine compound and preparation method and application thereof | 南京世其医药科技有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-20200190042-A1 | NOVEL 2,4,6-TRISUBSTITUTED S-TRIAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | ALUDA PHARMACEUTICALS, INC. | 2020-06-18 | — | — | US | disclosed |
| US-10611736-B2 | 2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof | ALUDA PHARMACEUTICALS, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190144399-A1 | NOVEL 2,4,6-TRISUBSTITUTED S-TRIAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | NANJING SHIQI PHARMACEUTICAL CO. LTD. (CN) | 2019-05-16 | — | — | US | disclosed |
| EP-3456712-A1 | NOVEL 2,4,6-TRISUBSTITUTED S-TRIAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | Nanjing Shiqi Pharmaceutical Co. Ltd. (CN) | 2019-03-20 | — | — | EP | disclosed |
| CN-109311825-A | Novel 2,4,6- tri- replaces s-triazine and its preparation method and application | 南京世其医药科技有限公司 | 2019-02-05 | — | — | CN | disclosed |
| WO-2010144522-A1 | UREIDOPHENYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390591-B2 | 2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof | VIM, HASPIN, WASF2 | MAPT 1535/4885RAB9A 2349/4885MEN1 1380/4885 |
| US-20190144399-A1 | NOVEL 2,4,6-TRISUBSTITUTED S-TRIAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | VIM, HASPIN, WASF2 | MAPT 1941/4885RAB9A 2149/4885MEN1 1503/4885 |
| US-10611736-B2 | 2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof | VIM, HASPIN, WASF2 | MAPT 1535/4885RAB9A 2349/4885MEN1 1380/4885 |
| US-20200190042-A1 | NOVEL 2,4,6-TRISUBSTITUTED S-TRIAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | VIM, HASPIN, WASF2 | MAPT 1941/4885RAB9A 2149/4885MEN1 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.